Brief: Ovid Therapeutics Q1 EPS USD -0.12
12/05/2026 12:00
May 12 (Reuters) - Ovid Therapeutics Q1 operating expenses USD 17.846 million. Q1 net income USD -16.988 million
Recent news on Ovid Therapeutics
See all newsOvid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors